期刊
CANCER LETTERS
卷 374, 期 1, 页码 31-43出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.01.050
关键词
Drug delivery; Nanocarrier; Cancer therapy; Combination therapy; Stimuli-activated therapy
类别
资金
- National Research Foundation of Korea [2014M3A9E5073316, 2014M3C1A3054141]
- Korea Health Industry Development Institute [HI15C1540]
- Intramural Research Program of KIST
- Ministry of Science, ICT & Future Planning, Republic of Korea [2E26360] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Foundation of Korea [2014M3A9E5073316, 2014M3C1A3054141] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Nanocarriers (NCs) are a group of nano-sized vehicles devised to deliver drugs to targeted malignant tissues or organs that provide remarkably improved targeting efficiency and therapeutic efficacy for cancer therapy. A variety of NCs have been developed to accommodate appropriate loading and release of drugs with a wide spectrum of chemical and physical characteristics. In addition, physicochemical modifications to the surface or interior of NCs allow for modulation of pharmacokinetic features reflecting clinical demands. However, cancer-related mortality is still high and drug-mediated cancer treatment remains a challenging research field despite the remarkable advances in targeting efficiency and therapeutic efficacy resulting from NCs. In this review, we focus on typical approaches and recent trends in NC-mediated drug delivery systems and their potential for targeted cancer therapy. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据